Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMMAT for recurrent or progressive pediatric CNS tumors
2024-515626-92-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Oct 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of bevacizumab, thalidomide, celecoxib, fenofibrate, cyclophosphamide and 4 more in medulloblastoma, ependymoma, Atypical teratoid rhabdoid tumor (ATRT) and 1 more (5 arms), sponsored by Medical University of Vienna. Primary endpoint: Response probability / recurrence-free probability. Planned start Oct 2013; status: authorised.
02
Drugs
bevacizumabthalidomidecelecoxibfenofibratecyclophosphamide
03
Conditions
medulloblastomaependymomaAtypical teratoid rhabdoid tumor (ATRT)central nervous system tumor
Beyond the preview
Go deeper on 2024-515626-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515626-92-00.